Cost-Effectiveness of Nivolumab in Combination with Ipilimumab in First-Line Treatment of Advanced Melanoma in Three European Countries Using 28-Month Overall Survival from Checkmate 067

Autor:	A Hirst, VF Paly, F Diamantogiannis, C Guilmet, S C Polanco, J Sabater, O Chirita
Rok vydání:	2017
Předmět:	Health Policy Public Health Environmental and Occupational Health
Zdroj:	Value in Health. 20:A432
ISSN:	1098-3015
DOI:	10.1016/j.jval.2017.08.197
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b13b7b0877769c708b8cd69e11f1b689 https://doi.org/10.1016/j.jval.2017.08.197 Zobrazit plný text záznamu Full Text from ScienceDirect